Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma

Overview of attention for article published in Frontiers in Pharmacology, August 2023

Altmetric Badge

Mentioned by

So far, Dimensions has found 1 citation of this research output.

The most recent citing publication is shown below. View this citation on Dimensions.

Article in Digestive Diseases and Sciences (May 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.